標準リスクの多発性骨髄腫と新たに診断された参加者を対象とした、ダラツムマブ、ボルテゾミブ、レナリドミドおよびデキサメタゾンによる導入後のCilta-cel、タルケタマブとダラツムマブの併用およびテクリスタマブとダラツムマブの併用の異なるシーケンスの研究 (aMMbition)
チルタカブタゲン オートロイセル (Cilta-cel)、タルケタマブ SC とダラツムマブ SC の併用 (Tal-D)、およびテクリスタマブ SC とダラツムマブ SC の併用 (Tec-D) のさまざまな配列の有効性と安全性を評価する第 2 相非盲検試験)新たに多発性骨髄腫と診断された標準リスクの参加者におけるダラツムマブ、ボルテゾミブ、レナリドミドおよびデキサメタゾン(DVRd)による導入後
The purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment. This is defined as a composite of sustained (at least 2 years) minimal residual disease (MRD) negativity with complete response/stringent complete response (CR/sCR) and a positron emission tomography/computed tomography (PET/CT) scan that does not show any signs of cancer at 5 years. MRD negativity and CR/sCR is defined as no detectable signs of remaining cancer cells after the treatment. This study will also characterize how well the treatments administered work in the study through progression-free survival (PFS). PFS is defined as the length of time during and after the treatment of a disease, that a participant lives with the disease, but it does not get worse.
調査の概要
状態
条件
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- City of Hope
-
San Francisco、California、アメリカ、94143
- University of California San Francisco
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa Hospital and Clinics
-
-
New York
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28204
- Levine Cancer Institute
-
-
-
-
-
Melbourne、オーストラリア、3004
- The Alfred Hospital
-
Melbourne、オーストラリア、3000
- Peter MacCallum Cancer Centre
-
-
-
-
-
Madrid、スペイン、28041
- Hosp. Univ. 12 de Octubre
-
Salamanca、スペイン、37007
- Hosp Clinico Univ de Salamanca
-
Santander、スペイン、39008
- Hosp. Univ. Marques de Valdecilla
-
-
-
-
-
Heidelberg、ドイツ、69120
- Universitaetsklinikum Heidelberg
-
Tübingen、ドイツ、72076
- Universitaetsklinikum Tuebingen
-
Würzburg、ドイツ、97080
- Universitatsklinikum Wurzburg
-
-
-
-
-
Salvador、ブラジル、41253-190
- IDOR - Regional Bahia
-
São Paulo、ブラジル、01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo、ブラジル、05652 900
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participants with documented new diagnosis of multiple myeloma (MM) according to international myeloma working group (IMWG) diagnostic criteria and with no prior myeloma-directed therapy
- Participants must have standard-risk MM (stage I and II) based on revised International Staging System (R-ISS)
- Participants must be considered fit (score equals to [=] 0) or intermediate-fit (score=1) according to IMWG Frailty Index assessment (based on the Charlson Comorbidity Index, the Katz Activity of Daily Living and the Lawson Instrumental Activities of Daily Living)
- Measurable disease defined as: Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL) (>=10 gram per liter [g/L] for institutions using alternative units) or urine M-protein level >= 200 milligrams per 24 hours (mg/24 hours); Light chain MM without measurable disease in the serum or the urine: Serum immunoglobulin free light chain >=10 milligrams per deciliter (mg/dL) (>=100 mg/L for institutions using alternative units) and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
Exclusion Criteria:
- Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM). Any history of malignancy, other than MM, which is considered at high risk of recurrence requiring systemic therapy
- Peripheral neuropathy or neuropathic pain of Grade >= 2, as defined by National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
- Known active or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM
- Stroke or seizure within 6 months of signing the informed consent form (ICF)
- Plasma cell leukemia at the time of diagnosis or any time thereafter through apheresis (>= 5 percent [%] circulating plasma cells in peripheral blood smears), Waldenstrom macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes(POEMS) syndrome, or primary amyloid light chain amyloidosis with associated organ dysfunction
- Presence of high-risk disease features: (a) Cytogenetic high risk lesions by MM fluorescence in situ hybridization (FISH) including deletion 17p (del[17p])/, t(4;14), t(14;16), amplification 1q (amp[1q21]) (>= 4 copies); (b) Presence of 1 or more extramedullary plasmacytomas
- Seropositive for human immunodeficiency virus (HIV)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Cohort A: DVRd Induction + Tal-D Consolidation + Cilta-cel
Participants will undergo apheresis followed by 4 cycles of DVRd induction (each cycle is of 28 days) and cilta-cel will be generated from the participants' T-cells selected from the apheresis product. Upon completion of cilta-cel production, product release, and completion of induction, participants will begin consolidation with 4 cycles of Tal-D (each cycle is of 28 days), followed by a conditioning regimen (cyclophosphamide and fludarabine daily for 3 days); cilta-cel will be administered 5 to 7 days after the start of the conditioning regimen. |
Talquetamab will be administered subcutaneously.
他の名前:
Cilta-cel infusion will be administered intravenously.
他の名前:
Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.
他の名前:
Bortezomib will be administered subcutaneously as a part of induction. Lenalidomide will be administered orally as a part of induction. Dexamethasone will be administered orally as a part of induction. Cyclophosphamide will be administered intravenously as a part of conditioning regimen. Fludarabine will be administered intravenously as a part of conditioning regimen. |
|
実験的:Cohort B: DVRd Induction + Cilta-cel + Tal-D and Tec-D Consolidation
Participants will undergo apheresis followed by 4 cycles of DVRd induction and Cilta-cel will be generated from the participants' T-cells selected from the apheresis product. Upon completion of cilta-cel production, product release and completion of induction, participants will begin consolidation with a conditioning regimen (cyclophosphamide and fludarabine daily for 3 days) with infusion of cilta-cel 5 to 7 days after the start of the conditioning regimen. Following cilta-cel infusion, alternating cycles of Tal-D (Cycle 1, 3, 5, and 7) and Tec-D (Cycle 2, 4, 6, and 8) will be started, no earlier than Day 84 and no later than Day 168 post cilta-cel infusion. Each cycle of Tal-D or Tec-D is 84 days which includes an extended treatment-free interval. |
Talquetamab will be administered subcutaneously.
他の名前:
Teclistamab will be administered subcutaneously.
他の名前:
Cilta-cel infusion will be administered intravenously.
他の名前:
Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.
他の名前:
Bortezomib will be administered subcutaneously as a part of induction. Lenalidomide will be administered orally as a part of induction. Dexamethasone will be administered orally as a part of induction. Cyclophosphamide will be administered intravenously as a part of conditioning regimen. Fludarabine will be administered intravenously as a part of conditioning regimen. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Rate of Response with Curative Potential
時間枠:Up to 5 years
|
Rate of Response with curative potential is defined as the percentage of participants with a composite of durable (at least 2 years) minimal residual disease (MRD) (10^-5) negativity with complete response/stringent complete response (CR/sCR) by serology and negative positron emission tomography/computed tomography (PET/CT) imaging at 5-years after start of induction therapy. This includes: negative imaging at 5-year landmark time; MRD-negative status (at 10^-5) in 2 bone marrow examinations that are a minimum of 2 years apart; response of CR or better per the International Myeloma Working Group (IMWG) criteria; no examination showing MRD-positive status or relapse from CR in between assessments. |
Up to 5 years
|
|
Progression Free Survival (PFS) Rate at 3-Year
時間枠:At 3-year
|
PFS is defined as the time from the date of randomization to either progressive disease (PD), according to the IMWG response criteria, or death, whichever occurs first. |
At 3-year
|
|
PFS Rate at 5-Year
時間枠:At 5-year
|
PFS is defined as the time from the date of randomization to either PD, according to the IMWG response criteria, or death, whichever occurs first. |
At 5-year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall response rate (ORR; Partial response [PR] or better)
時間枠:Up to 5 years
|
ORR (PR or better) is defined as the percentage of participants with best overall response of PR or better according to IMWG response criteria. |
Up to 5 years
|
|
CR or Better Rate
時間枠:Up to 5 years
|
Rate of CR or better is defined as the percentage of participants with best overall response of CR or better according to IMWG response criteria. |
Up to 5 years
|
|
Very Good Partial Response (VGPR) or Better Rate
時間枠:Up to 5 years
|
Rate of VGPR or better is defined as the percentage of participants with best overall response of VGPR or better rate according to IMWG response criteria. |
Up to 5 years
|
|
Duration of Response (DOR)
時間枠:Up to 5 years
|
DOR is calculated among responders (with a PR or better response) from the date of initial documented response (PR or better) to the date of first documented evidence of PD as defined according to IMWG criteria or death due to any cause, whichever occurs first. |
Up to 5 years
|
|
Time to First Response (TTR)
時間枠:Up to 5 years
|
Time to response (that is, time to first response) is defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for PR or better based on the computerized algorithm per IMWG criteria for those who had PR or better as their best response. |
Up to 5 years
|
|
Duration of CR or Better Response
時間枠:Up to 5 years
|
Duration of CR or better response is calculated among responders (with a CR or better response) from the date of initial documented response CR or better to the date of first documented evidence of PD as defined according to IMWG criteria or death due to any cause, whichever occurs first. |
Up to 5 years
|
|
Time to First CR or Better Response
時間枠:Up to 5 years
|
Time to first CR or better response is defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for CR or better based on the computerized algorithm per IMWG criteria. |
Up to 5 years
|
|
PFS on next line therapy (PFS2)
時間枠:Up to 5 years
|
PFS2 is defined as time from randomization to progression on the next line of therapy or death, whichever comes first. |
Up to 5 years
|
|
Overall Survival (OS)
時間枠:Up to 5 years
|
OS is measured from the date of randomization to the date of death due to any cause. |
Up to 5 years
|
|
MRD-negative CR Rate
時間枠:Up to 5 years
|
MRD-negative CR is defined as the percentage of participants who achieved both CR or better and MRD negativity at a threshold of 10^-5 and 10^-6. MRD-negative CR rate will be evaluated at the first occurrence from induction treatment initiation for participants per IMWG criteria. |
Up to 5 years
|
|
Number of Participants with Treatment-emergent Adverse Events (TEAEs) by Severity
時間枠:Up to 5 years
|
An Adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. Severity of TEAEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse events. |
Up to 5 years
|
|
Change from baseline in Health-related quality of life (HRQoL) (symptoms and functioning) using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core 30 item instrument (EORTC-QLQ-C30)
時間枠:Up to 5 years
|
Change from baseline in participants' HRQoL (symptoms and functioning) as assessed by EORTC-QLQ-C30 will be reported. The EORTC-QLQ-C30 includes 30 items in 5 functional scales (physical, role, emotional, cognitive, social), 1 global health status scale, 3 symptom scales (pain, fatigue, nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). The recall period is 1 week ("past week") and responses are reported using a verbal rating scale. The item and scale scores are transformed to a 0-to-100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms. |
Up to 5 years
|
協力者と研究者
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 血管疾患
- 心血管疾患
- 新生物
- 免疫系疾患
- 組織型別の新生物
- 血液疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- 新生物、形質細胞
- 止血障害
- パラタンパク血症
- 血液タンパク質障害
- 出血性疾患
- ヘミックおよびリンパ疾患
- 多発性骨髄腫
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 炭化水素
- カルボン酸
- 多環式化合物
- ピペリジン
- 無機化学物質
- 妊娠
- 妊娠
- ステロイド
- 融合リング化合物
- ステロイド、フッ素化
- ホスホルアミドマスタード
- 窒素マスタード化合物
- マスタード化合物
- 炭化水素、ハロゲン化
- ホスホラミド
- 有機リン化合物
- 妊娠症
- ボロン酸
- 酸、非カルボン酸
- 酸
- ホウ素化合物
- ピラジン
- フタリミド
- フタル酸
- 酸、炭素環
- ピペリドン
- イソインドール
- レナリドミド
- ボルテゾミブ
- デキサメタゾン
- シクロホスファミド
- フルダラビン
- ダラトゥムマブ
- タルケタマブ
その他の研究ID番号
- 54767414MMY2093
- 54767414MMY2093 (その他の識別子:Janssen Research & Development, LLC)
- 2023-505792-71-00 (レジストリ識別子:EUCT number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。